All News
Identifying Gaps in axSpA: Lessons from European Map of Axial Spondyloarthritis (EMAS)
Despite the increasing scientific knowledge on axSpAs, a substantial gap still remains. Delay in diagnosis continues to pose a threat in the early identification of patients and those already on treatment may deal with additional issues such as work productivity or quality of life.
Read Article
Opening Day Report
The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and interview with Dr. Seema Yasmin (Stanford).
Read Article
Emerging Therapies in Spondyloarthritis: A Promising Pipeline
Growing awareness of spondyloarthropathies over the last two decades has led to a better understanding of the pathophysiology of spondyloarthritis, and subsequently increased interest in more distinct, disease state specific treatment options.
Read Article
6 year f/up study of sacroilitis in nr-AxSpA pts
⭐️~10% of pts progressed from nr-AxSpa to AS every 2 years
Abs#907
#ACR21
@RheumNow
https://t.co/kiWGmKhpWu
Robert B Chao, MD doctorRBC ( View Tweet)
There are no MRI imaging difference in axSpA with psoriasis, coliitis or iritis. 240 patients in the SASPIC study show psoriatic axSpA similar to axSpA associated with iritis or colitis. Supports the umbrella concept of axSpA @RheumNow #ACR21 Abst#0902 https://t.co/VKTUv22hEJ https://t.co/lOL82ceSn9
Dr. Antoni Chan synovialjoints ( View Tweet)
Great start to #ACR21 and great recap of the year in rheumatology.
Positive data on tofacitinib and AS but still pending approval.
Where would JAKinibs be in your AS treatment algorithm?🤔
@RheumNow https://t.co/cs8U33355A
Robert B Chao, MD doctorRBC ( View Tweet)
#ACR21 Abst#0910 by @rheum_cat. Do TNFi ⬆️ risk of incident HTN in AxSpa?
⭐️PSOAS cohort: Prosp study from 2003-2018
▶️When adjusted for confounders (obesity, disease activity, NSAID use), insufficient evidence to show ⬆️ risk of HTN w TNFi
https://t.co/DCZ3W8CkOa @Rheumnow
Links:
Eric Dein ericdeinmd ( View Tweet)
#ACR21 Abst#0916. https://t.co/uc5JDVY0ud
Your patient has had 1 yr of remission of AxSpa on Certolizumab pegol, tolerating the medication. What do you recommend @Rheumnow
Links:
Eric Dein ericdeinmd ( View Tweet)
Ouch! Patients with AS can fracture with minor trauma
#ACR21 Radiology Bootcamp https://t.co/1piKvKUM2w
TheDaoIndex KDAO2011 ( View Tweet)
#ACR21 Radiology Bootcamp-- pretty helpful if you're studying for #ABIMRheumBoards
Do you know how to distinguish sacroiliitis from pseudo-sacroiliitis? https://t.co/btS8mm8yH8
TheDaoIndex KDAO2011 ( View Tweet)
Excellent talk by Dr. Anna Molto. Characteristics of spondyloarthritis, noting some patients with PsA have radiographic and non-radiographic axial SpA.
#ACR21 6S403 @RheumNow https://t.co/ycftOMrWO9
Pedro Castillo _Castillo_Pedro ( View Tweet)
Excellent scientific session on #SpA at #ACR21 right now- especially like this clear diagram of pathophysiology and useful summary slide from Dr Nigil Haroon on differences between #axSpA and axial #PsA
@RheumNow https://t.co/F7Ns7e9HQI
Mrinalini Dey DrMiniDey ( View Tweet)
“The differences and similarities between axial disease in psoriatic arthritis vs axial spondyloarthritis is just at the cusp of discovery” Nigil Haroon at session 6S403 @RheumNow #ACR21
Dr. Antoni Chan synovialjoints ( View Tweet)
My first video for #ACR21 for @RheumNow, discussing #SickLeave, #WorkParticipation and #WorkDisability in patients with #SpA, with a focus on abstracts 0380 and 0381 by @ElenaNikiUK
#axspa #spondyloarthritis #arthritis #qualityoflife
Watch it here👇🏼
https://t.co/MEQ4wkFxrx
Mrinalini Dey DrMiniDey ( View Tweet)
Torgutalp et al.
⭐️Included Early axSpA - 166 nr-axSpA (symptom duration ≤5 y) and 135 with r-axSpA (symptom duration ≤10 y) from German Cohort
⭐️Assessed TNFI use over 2 years and has shown🔽 in radiographic sacroiliitis progression.
Abst#0451 #ACR21 @RheumNow #ACRBest https://t.co/xP0wMLSyGw
swethaann23 swethaann23 ( View Tweet)
IL-22 as a potential biomarker of AxSpA from non-inflammatory mimickers?
⬆️IL-22 in AxSpA vs. controls
⭐️IL-22 did not correlate w/ mSASSS, BASADI, ASDAS, CRP
Abs#385
#ACR21
@RheumNow https://t.co/hNtStAluJH
Robert B Chao, MD doctorRBC ( View Tweet)
2 year study of AxSpA pts in clinical remission who tapered TNFi.
⭐️52% successfully tapered to either 2/3, 1/2 or 1/3 dose
⭐️Baseline physician global score independent predictor of successful tapering
Abs#364
#ACR21
@RheumNow
https://t.co/9Kti5JGMYr https://t.co/y1Uj2dTABC
Robert B Chao, MD doctorRBC ( View Tweet)
@ericdeinmd @RheumNow *TICOSPA
IMO, more an issue of poor tools for activity monitoring and insufficiently diverse toolbox. Works in RA as lots of choices and good activity measures. Until AxSpa has those, don’t see how we hope to meet “tight control”.
Ethan Craig rheumecraig ( View Tweet)
Irish registry of AS pts included 76 women who were pregnant
⭐️58% uncomplicated, 41.9% complicated, 11% multiple complications
⭐️frequency of miscarriage ⬆️
⭐️complications included C-section, preterm, NICU admission
#ACR21
@RheumNow
Abs#369 https://t.co/90dolEeTIw
Robert B Chao, MD doctorRBC ( View Tweet)
Self-monitoring app for AxSpA pts
⭐️adherence over 6 months poor 😔
⭐️high disease activity and older age related to ⬆️frequency of reporting
Abs#373
#ACR21
@RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
